Last reviewed · How we verify
Goat Milk
Goat Milk, marketed by the City of Hope Medical Center, is a topical skin use product with a key composition patent expiring in 2028. Its primary strength lies in its unique mechanism of action, which differentiates it in the topical skin care market. The primary risk is the lack of revenue data and key trial results, which may limit its competitive positioning and investor confidence.
At a glance
| Generic name | Goat Milk |
|---|---|
| Sponsor | City of Hope Medical Center |
| Drug class | Non-Standardized Chemical Allergen [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Topical Skin Use
Common side effects
Key clinical trials
- Goat or Cow Milk Based Infant Formula GMS (PHASE2, PHASE3)
- Gastrointestinal Symptoms and Tolerance in Infants Fed Goat or Cow's Milk-based Infant Formula (NA)
- Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant (PHASE1)
- Goat vs. Cow Milk Digestive Tolerance (NA)
- Goat Milk-Derived Formula vs. Undiluted Goat Milk in Infants Unable to Exclusively Breastfeed: Growth and Biomarker Analysis (NA)
- An Exploratory RWE Study Exploring Effects of a Goat Milk Based Young Child Formula on Health Benefits (NA)
- Tolerability of Goat Milk Protein in Eosinophilic Esophagitis Patients With Cow Milk Protein Trigger (NA)
- GI Symptoms in Infants Fed Goat Milk-based Infant Formula
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |